Molecular diagnosis in allergology, particularly using the ImmunoCAP ISAC 112 microarray, improves identification of specific allergens in patients, enhancing the understanding of their allergies.
A study conducted in Catalonia assessed this method's impact on diagnosis and treatment (specifically immunotherapy) in young patients with allergic conditions, showing significant shifts in treatment plans.
Results indicated that over half of the patients (51%) had changes in their immunotherapy prescriptions based on molecular diagnostic findings, suggesting this approach leads to better-targeted treatments.